The current study's objective is to create and evaluate an effervescent-based sustained-release floating drug delivery system (FDDS) for carvedilol that has a 12-hour dissolving time to reduce the frequency of its administration. Over the past 20 years, there has been a huge desire for more dosage forms that are acceptable to patients. Because of this, their technologies are more in demand than ever. Since creating a new chemical entity is very expensive, pharmaceutical companies are focusing on creating novel drug delivery systems for their existing medications that have improved efficacy and bioavailability, along with a lower dose frequency to lessen side effects.